Jaundice differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Jaundice is yellowish discoloration of the skin, conjunctiva, and mucous membranes caused by hyperbilirubinemia. Usually, the concentration of bilirubin in the blood must exceed 2β3 mg/dL for the coloration to be easily visible.
Differential diagnosis of jaundice
For the differential diagnosis for jaundice and RUQ pain, click here.
For the differential diagnosis for jaundice and pruritis, click here.
For the differential diagnosis for jaundice and fever, click here.
For the differential diagnosis for jaundice, fever, and RUQ pain, click here.
For the differential diagnosis for jaundice, pruritis and RUQ pain, click here.
Differential diagnosis of jaundice are: [1][2][3][4][5]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- β Fargo MV, Grogan SP, Saguil A (2017). “Evaluation of Jaundice in Adults”. Am Fam Physician. 95 (3): 164β168. PMIDΒ 28145671.
- β Leevy CB, Koneru B, Klein KM (1997). “Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease”. Gastroenterology. 113 (3): 966β72. PMIDΒ 9287990.
- β Hov JR, Boberg KM, Karlsen TH (2008). “Autoantibodies in primary sclerosing cholangitis”. World J. Gastroenterol. 14 (24): 3781β91. PMCΒ 2721433. PMIDΒ 18609700.
- β Bond LR, Hatty SR, Horn ME, Dick M, Meire HB, Bellingham AJ (1987). “Gall stones in sickle cell disease in the United Kingdom”. Br Med J (Clin Res Ed). 295 (6592): 234β6. PMCΒ 1247079. PMIDΒ 3115390.
- β Malakouti M, Kataria A, Ali SK, Schenker S (2017). “Elevated Liver Enzymes in Asymptomatic Patients – What Should I Do?”. J Clin Transl Hepatol. 5 (4): 394β403. doi:10.14218/JCTH.2017.00027. PMCΒ 5719197. PMIDΒ 29226106.
Β© 2026 MyEClinic β IFTM Institut fΓΌr Telematik in der Medizin GmbH
